FY4/20 1Q
Supplementary Materials

August 30, 2019

１．Consolidated Results■Year-on-Year
FY4/19 1Q
results

FY4/20 1Q
results

YoYchange(¥ million)
YoYchange(%)

Net sales

65,013

72,461+7,448+11.5

Gross profit

10,687

11,490+803+7.5

SG&A expenses

7,236

7,568+332+4.6

Operating income

3,450

3,921+471+13.7

Ordinary income

3,610

4,212+602+16.7

Profit attributableto owners of parent

1,851

2,240+389+21.0

Earnings pershare(¥)

52.27

63.24+10.97+21.0% of net sales% of net sales% of net sales% of net sales

16.4

15.9

11.1

10.4

5.3

5.4

5.6

5.8

2.8

% of net sales

3.1

Figures in the table are rounded down

■Vs Plan
FY4/20 1Q
plan

FY4/20 1Q
results

Vs planchange(¥ million)
Vs planchange(%)

Net sales

71,14072,461+1,321+1.9

Gross profit

11,59011,490(100)(0.9)

SG&A expenses

7,700

7,568(132)(1.7)

Operating income

3,890

3,921+31+0.8

Ordinary income

4,020

4,212+192+4.8

Profit attributableto owners of parent

2,100

2,240+140+6.7

Earnings pershare(¥)

59.28

63.24+3.96+6.7% of net sales% of net sales% of net sales% of net sales

16.3

15.9

10.8

10.4

5.5

5.4

5.7

5.8

3.0

% of net sales

Figures in the table are rounded down

3.1-1-

２. Segment Information（Dispensing Pharmacy Business）■Year-on-Year
FY4/19 1Q
results

FY4/20 1Q
results(¥ million)
YoYchange(%)

YoYchange

Net sales

57,09064,800+7,710+13.5

Gross profit

7,416

8,409+993+13.4

SG&A expenses

3,576

3,738+162+4.5

Operating income

3,839

4,671+832+21.7

Segment income

3,984

4,804+820+20.6% of net sales% of net sales% of net sales% of net sales

13.0

13.0

6.3

5.8

6.7

7.2

7.0

7.4

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income■Vs Plan

FY4/20 1Q
plan

FY4/20 1Q
results(¥ million)
Vs planchange(%)

Vs planchange

Net sales

62,88064,800+1,920+3.1

Gross profit

8,310

8,409+99+1.2

SG&A expenses

3,610

3,738+128+3.5

Operating income

4,700

4,671(29)(0.6)

Segment income

4,810

4,804(6)(0.1)% of net sales% of net sales% of net sales% of net sales

13.2

13.0

5.7

5.8

7.5

7.2

7.6

7.4

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income-2-3. Segment Information（Cosmetic and Drug Store Business）■Year-on-Year
FY4/19 1Q
results

FY4/20 1Q
results

YoYchange(¥ million)
YoYchange(%)

Net sales

6,505

6,560+55+0.8

Gross profit

2,403

2,495+92+3.8

36.9

38.0

SG&A expenses

2,057

2,277+220+10.7

Operating income

345217(128)(37.1)

Segment income

364230(134)(36.8)% of net sales% of net sales% of net sales% of net sales

31.6

34.7

5.3

3.3

5.6

3.5

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income■Vs Plan
FY4/20 1Q
plan

FY4/20 1Q
results

Vs planchange(¥ million)
Vs planchange(%)

Net sales

7,000

6,560(440)(6.3)

Gross profit

2,620

2,495(125)

(4.8)

37.4

38.0

SG&A expenses

2,330

2,277(53)(2.3)

Operating income

290217(73)(25.2)

Segment income

293230(63)(21.5)% of net sales% of net sales% of net sales% of net sales

33.3

34.7

4.1

3.3

4.2

3.5

Figures in the table are rounded down
Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income-3-4. Sales Verification（%）■Dispensing Pharmacy Business（Vs Plan）（%）
Average
Average
Prescription
Prescription
Net salesprescriptionprescription
volumevolumeprice
price■Dispensing Pharmacy Business (YoY）
Net sales
Same store (964)Store openings in theprevious year (152)

Total (1,120)

(1.2)

+3.4

Same store (964)+3.0+1.3+1.7+8,161.9 +5,607.9+44.4

Store openings in theprevious year (152)+3.4+2.6+0.8

Total (1,120)+3.0+1.1+1.7+2.2+13.4+9.8

3.4■Cosmetic and Drug Store Business（YoY） （%）■Cosmetic and Drug Store Business (Vs Plan）（%）
Average
Number ofspending percustomers
customer

Net sales
Same store (45)Store openings in theprevious year (7)Total (55)

(4.4)

(0.1)

(4.3)

---

+0.8

+5.6

(4.5)

Net sales

Average
Number ofspending percustomers
customerSame store (45)

(6.5)

(0.6)

(6.0)

Store openings in theprevious year (7)

+4.1

+7.7

(3.4)

Total (55)

(6.3)

(0.4)

(5.9)

-4-

5. Consolidated Balance Sheet■Assets
Cash on hand and in banks
Notes and accounts receivable
Inventories
Total current assets
Buildings and structures,net
Land
Lease assets
Total property,plant andequipment
Goodwill
Lease assetsTotal intangible fixed assets
Investments in securities
Deferred tax assets
Deposits and guarantees
Total investments and otherassets
Total fixed assets
Total deferred assets
Total assets(¥ million)
End-FY4/19 1Q

End-FY4/19

End-FY4/20 1Q

Change61,725
11,511
11,227
94,685
14,773
10,197733

48,091
12,771
12,89885,446
16,352
10,394571

40,753
15,94013,987
83,311
16,355
10,484487(7,338)+3,169+1,089(2,135)+3+90(84)27,88430,18630,216+30

37,266
10
39,285
2,320
3,819
11,41445,2497
47,577
1,795
4,284
15,13344,216
6
46,6301,820
4,276
15,078(1,033)(1)(947)+25(8)(55)

20,71525,751

26,336+585

87,885
92
182,663

103,51559
189,021103,184
48
186,543(331)(11)(2,478)Figures in the table are rounded down

Change:End-FY4/20 1Q compared with end-FY4/19
Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees)
totaled ¥1,102million(¥ million)■Liabilities and Net Assets

End-FY4/19 1Q

End-FY4/19End-FY4/20 1Q

Total liabilities and net assets

41,646
7,486
399
70,73910,052504
15,10685,846
21,89420,50054,34996,743
96,816
182,663

Figures in the table are rounded down

Change:End-FY4/20 1Q compared with end-FY4/19

Accounts payable
Short-term debt
Lease obligations
Total current liabilities
Long-term debt
Lease obligations
Total long-term liabilities
Total liabilities
Common stock
Capital surplus
Retained earnings
Total shareholders’ equity
Total net assets

44,794
5,571
318
73,744
5,985
401
11,35585,099
21,89420,50061,526
103,920
103,922
189,021-5-

46,194
5,045
286
71,9675,014
330
10,421
82,38921,89420,50061,818104,212104,154
186,543

Change+1,400
(526)
(32)
(1,777)
(971)
(71)
(934)
(2,710)+292+292+232(2,478)

6. FY4/20 Plan (Consolidated)

FY4/18results

FY4/19results(¥ million)

YoYchangeFY4/20plan

YoYchange (%)

Net sales

268,385

275,596

300,330+24,734+9.0

Gross profit

47,99345,36350,540+5,177+11.4

28,37029,29531,840+2,545+8.7

19,622

16,067

18,700+2,633+16.4

20,12916,637

19,200+2,563+15.4

Profit attributableto owners of parent

10,567

9,029

10,130+1,101+12.2

Earnings pershare(¥)

310.08254.87285.94+31.07+12.2

Annual dividend (¥)

50.00

55.00

55.00

-0.0

% of net sales

SG&A expenses% of net sales

Operating income% of net sales

Ordinary income% of net sales% of net sales

17.9

10.6

7.3

7.5

3.9

16.5

10.6

5.8

6.0

3.3

Figures in the table are rounded down
Change:FY4/20 plan compared with FY4/19 results-6-16.8

10.66.26.43.4

7. Transition of Store Openings■Number of Store Openings in Dispensing Pharmacy Business
FY4/12 FY4/13 FY4/14 FY4/15 FY4/16 FY4/17 FY4/18 FY4/19

FY4/201QOrganic

27383640322725233

M&A283826119110182

11134

2Total494560616754881

1,066

1,029

1,1321,120■Number of Store Openings in Cosmetic and Drug Store Business
FY4/12 FY4/13 FY4/14 FY4/15 FY4/16 FY4/17 FY4/18 FY4/19

FY4/201QOrganic

773359473Total

56

61

59

56

52

52

48

54

55

Inquiries related to this presentation should be addressed toAIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
https://www.ainj.co.jp/This document may not be reproduced or distributed to any third party without
prior approval of AIN HOLDINGS INC. This document has been prepared for
information purpose only and does not form part of a solicitation to sell orpurchase any securities. Information contained herein may be changed orrevised without prior notice. This document may contain forecasting statements
as to future results of operations. No forecast statement can be guaranteed andactual results of operations may differ from those projected.

-7-